RE: RNS5 Dec 2023 21:58
One of the flaws cited in many research papers regarding liquid biopsies is the lack of standardisation. This is something that AGL has sought to address with the Portrait+ Kit.
From the RNS - “performance of current CTC protocols being used by academic and research institutions varies considerably. ANGLE has developed its test for reliable repeatable results with a fully validated, standardised protocol to make it easy for customers……ANGLE's Portrait+ CTC staining kit provides investigators with accurate, repeatable, and precise identification of CTCs and hence has the potential to optimise study protocols and minimise cost.”
And from September’s Interim’s - “it's being offered as a product to be sold to customers around the world, not just from our clinical labs. And here we're taking the antibodies, that we've spent a couple of years working on, optimising these antibodies for the detection of cancer.
And we have basically productised them by lyophilising the antibodies down into essentially a solid powder form which makes them stable, so they can then be shipped, and they can be stored on a shelf. And the idea of this is that all our customers, external third party customers, can use the same antibodies that we've spent a lot of time optimising so they can then get consistent results with all of the other customers out there. And it makes it much, much easier for adoption. Because at the moment prior, to our launch of Portrait+, our customer’s who buy Parsortix have to define their own method to do antibodies and their own process in their lab. And that’s actually quite tricky, which means that the sale of the product is primarily limited to high quality labs, really top notch labs. What we can do now, and our aim is, we can democratise the use of this to make it super easy for anybody to use it. They just get this kit. They follow our instructions and they can then look under the microscope and get their own information. ..”
Sign In
Follow the stocks
